Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

807.05INR
27 Mar 2015
Change (% chg)

Rs-11.95 (-1.46%)
Prev Close
Rs819.00
Open
Rs823.00
Day's High
Rs829.00
Day's Low
Rs799.50
Volume
89,170
Avg. Vol
92,698
52-wk High
Rs844.00
52-wk Low
Rs344.00

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.46
Market Cap(Mil.): Rs342,744.31
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): -- 40.31 40.78
EPS (TTM): -19.13 -- --
ROI: -- 16.86 16.19
ROE: -- 17.40 17.04
Search Stocks

Sun Pharma open to large acquisitions post Ranbaxy

MUMBAI - India's largest drugmaker Sun Pharmaceutical Industries Ltd will look at making more large acquisitions even as it winds up a $3.2 billion deal to buy smaller rival Ranbaxy Laboratories Ltd.

25 Mar 2015

UPDATE 1-India's Sun Pharma open to large acquisitions post Ranbaxy deal

* To boost annual R&D spending to about $300 mln (Adds managing director comments)

25 Mar 2015

Indian shares edge down in cautious trade; Sun Pharma rises

MUMBAI, March 25 - Indian shares edged down on Wednesday to their near six-week lows and were heading for a sixth straight session of falls, as caution ahead of the expiry of monthly derivatives and the end of the fiscal year hit blue-chips such as Larsen & Toubro.

25 Mar 2015

India's Sun Pharma open to large acquisitions post Ranbaxy deal

MUMBAI, March 25 - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Wednesday its $3.2 billion acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.

25 Mar 2015

BUZZ-Investors take tactical refuge in Indian pharma ahead of Fed

** Pharmaceutical stocks, traditionally seen as defensives, gain on churning ahead of the U.S. Federal Reserve policy meeting outcome on Wednesday

17 Mar 2015

U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies

MUMBAI - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd's bid to reinstate approvals granted to it to launch the first copies of the heartburn drug Nexium and the antiviral Valcyte, a court document showed.

28 Feb 2015

U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies

MUMBAI - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd's bid to reinstate approvals granted to it to launch the first copies of the heartburn drug Nexium and the antiviral Valcyte, a court document showed.

28 Feb 2015

U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies

MUMBAI, Feb 28 - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd's bid to reinstate approvals granted to it to launch the first copies of the heartburn drug Nexium and the antiviral Valcyte, a court document showed.

28 Feb 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

Earnings vs. Estimates

Search Stocks